The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Carl R. who wrote (132)	2/5/2000 5:50:00 PM
From: Hank	Read Replies (2) of 207

"What would others do?" Well, if like me they happen to try Zicam for the first time on one of the varieties of colds that don't respond, I presume they would chalk it up to experience and not bother with Zicam again. The key question is that out of all the cold suffers in the world, how many have the type of cold that doesn't respond. This obviously relates to one of my original objections about Zicam in that nobody knows exactly how many of the 100+ serotypes of rhinovirus are responsive to zinc treatments. You'd think that would be a key question wouldn't you? In the case of pleconaril (VPHM) that question has been answered. Roughly 50% of all know rhinoviral strains are treatable with Pleconaril. Either GUMM knows the answer for Zicam and aren't telling or they don't want to know. After all, they say ignorance is bliss, or in this case good for ones stock price.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next